急性缺血性卒中再灌注治疗医疗质量评价与改进专家建议（2026）

doi:10.3969/j.issn.1673-5765.2026.03.010

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (3): 338-352.DOI: 10.3969/j.issn.1673-5765.2026.03.010

急性缺血性卒中再灌注治疗医疗质量评价与改进专家建议（2026）

国家神经系统疾病医疗质量控制中心，中国卒中学会医疗质量管理与促进分会，中国卒中学会神经介入分会

北京 100070
首都医科大学附属北京天坛医院，国家神经系统疾病医疗质量控制中心，神经系统疾病国家临床医学研究中心（李子孝，王拥军）
杭州 310009
浙江大学医学院附属第二医院神经内科（楼敏）

收稿日期:2025-11-09 修回日期:2026-01-19 接受日期:2026-02-22 出版日期:2026-03-20 发布日期:2026-03-20
通讯作者: 李子孝 lizixiao2008@hotmail.com 楼敏 loumingxc@vip.sina.com 王拥军 yongjunwang@ncrcnd.org.cn
基金资助:
国家重点研发计划（2022YFC2504900）
科技创新2030国家科技重大专项（2023ZD0505400；2023ZD0505401）

Expert Recommendations on Evaluation and Improvement of Healthcare Quality for Reperfusion Therapy in Acute Ischemic Stroke (2026)

Beijing Tiantan Hospital, Capital Medical University, National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, Beijing 100070, China (LI Zixiao, WANG Yongjun)
Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China (LOU Min)

Received:2025-11-09 Revised:2026-01-19 Accepted:2026-02-22 Online:2026-03-20 Published:2026-03-20
Contact: LI Zixiao, E-mail: lizixiao2008@hotmail.com LOU Min, E-mail: loumingxc@vip.sina.com WANG Yongjun, E-mail: yongjunwang@ncrcnd.org.cn

摘要/Abstract

摘要： 卒中已成为我国居民死亡和残疾的首位原因，其中缺血性卒中的占比超过80%。尽早开展再灌注治疗是改善急性缺血性卒中（acute ischemic stroke，AIS）患者预后的关键。在国家卫生健康委员会持续提高急性脑梗死再灌注治疗率政策的推动下，我国AIS再灌注治疗取得了显著成效。为巩固现有成果并持续提升缺血性卒中再灌注治疗的规范化水平，国家神经系统疾病医疗质量控制中心联合中国卒中学会组织专家，在2021年发表的《急性缺血性卒中再灌注治疗医疗质量评价与改进专家建议》基础上，修订形成本版更新的专家建议。本版建议参考国内外最新研究数据、我国医院质量监测系统（Hospital Quality Monitoring System，HQMS）的病案首页数据，以及我国多项大型登记研究的结果，更新了AIS再灌注治疗医疗质量评价的关键指标及可量化改进的目标值，旨在为卫生行政部门、医疗机构及医务人员开展科学、规范的医疗质量改进工作提供学术指导，并最终改善AIS患者的临床结局。

关键词: 缺血性卒中; 静脉溶栓; 血管内治疗; 再灌注; 医疗质量

Abstract: Stroke has emerged as the leading cause of death and disability among residents in China, with ischemic stroke accounting for over 80% of all cases. Timely administration of reperfusion therapy is critical to improving clinical outcomes in patients with acute ischemic stroke (AIS). Driven by policies from the National Health Commission to continuously improve the reperfusion therapy rate for acute cerebral infarction, substantial progress has been made in AIS reperfusion therapy in China. To build upon these achievements and further enhance the standardization of reperfusion therapy for ischemic stroke, the National Center for Healthcare Quality Management in Neurological Diseases, in collaboration with the Chinese Stroke Association, has convened experts to revise and formulate this updated version of the expert recommendations based on the 2021 version of Consensus on Evaluation and Improvement of Healthcare Quality of Acute Ischemic Stroke Reperfusion Therapy. This updated version incorporates the latest domestic and international research data, information from the Hospital Quality Monitoring System (HQMS), and findings from multiple large-scale registry studies in China. It updates key indicators for healthcare quality evaluation of AIS reperfusion therapy and sets quantifiable improvement targets. The aim is to provide scientific and standardized academic guidance for health administrative authorities, medical institutions, and healthcare professionals in their quality improvement efforts, and ultimately improve the clinical outcomes of patients with AIS.

Key words: Ischemic stroke; Intravenous thrombolysis; Endovascular treatment; Reperfusion; Healthcare quality

中图分类号:

国家神经系统疾病医疗质量控制中心, 中国卒中学会医疗质量管理与促进分会, 中国卒中学会神经介入分会. 急性缺血性卒中再灌注治疗医疗质量评价与改进专家建议（2026）[J]. 中国卒中杂志, 2026, 21(3): 338-352.

National Center for Healthcare Quality Management in Neurological Diseases, Medical Quality Management and Promotion Branch of the Chinese Stroke Association, Interventional Neuroradiology Branch of the Chinese Stroke Association. Expert Recommendations on Evaluation and Improvement of Healthcare Quality for Reperfusion Therapy in Acute Ischemic Stroke (2026)[J]. Chinese Journal of Stroke, 2026, 21(3): 338-352.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.chinastroke.org.cn/CN/10.3969/j.issn.1673-5765.2026.03.010

https://www.chinastroke.org.cn/CN/Y2026/V21/I3/338

参考文献

[1] WANG Y J，LI Z X，GU H Q，et al. China stroke statistics 2019：a report from the National Center for Healthcare Quality Management in Neurological Diseases，China National Clinical Research Center for Neurological Diseases，the Chinese Stroke Association，National Center for Chronic and Non-communicable Disease Control and Prevention，Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations[J]. Stroke Vasc Neurol，2020，5（3）：211-239.
[2] GU H Q，YANG X，WANG C J，et al. Clinical characteristics，management，and in-hospital outcomes in patients with stroke or transient ischemic attack in China[J/OL]. JAMA Netw Open，2021，4（8）：e2120745[2025-11-11]. https://doi.org/10.1001/jamanetworkopen.2021.20745.
[3] WANG Y J，LI Z X，WANG Y L，et al. Chinese Stroke Center Alliance：a national effort to improve healthcare quality for acute stroke and transient ischaemic attack：rationale，design and preliminary findings[J]. Stroke Vasc Neurol，2018，3（4）：256-262.
[4] BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J，2021，6（1）：1-62.
[5] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2025-11-11]. https://doi.org/10.1161/STR.0000000000000211.
[6] 中国卒中学会，中国卒中学会神经介入分会，中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志，2023，18（6）：684-711.
Chinese Stroke Association；Interventional Neuroradiology Branch of Chinese Stroke Association；Intervention Group，Committee of Stroke Prevention and Control，Chinese Preventive Medicine Association. Chinese guideline for endovascular treatment of acute ischemic stroke 2023[J]. Chin J Stroke，2023，18（6）：684-711.
[7] XIONG Y Y，LI S Y，WANG C J，et al. Chinese Stroke Association guidelines on reperfusion therapy for acute ischaemic stroke 2024[J]. Stroke Vasc Neurol，2025，10（5）：527-541.
[8] TURC G，BHOGAL P，FISCHER U，et al. European Stroke Organisation（ESO）-European Society for Minimally Invasive Neurological Therapy（ESMINT）guidelines on mechanical thrombectomy in acute ischemic stroke[J/OL]. J Neurointerv Surg，2019，11：535-538[2025-11-11]. https://doi.org/10.1136/neurintsurg-2018-014568.
[9] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志，2024，57（6）：523-559.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chin J Neurol，2024，57（6）：523-559.
[10] 中国卒中学会，《中国卒中学会急性缺血性卒中再灌注治疗指南2024》编写组. 中国卒中学会急性缺血性卒中再灌注治疗指南2024[J]. 中国卒中杂志，2024，19（12）：1460-1478.
Chinese Stroke Association，Writing Group of Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke 2024. Chinese Stroke Association guidelines on reperfusion therapy for acute ischemic stroke 2024[J]. Chin J Stroke，2024，19（12）：1460-1478.
[11] PRABHAKARAN S，GONZALEZ N R，ZACHRISON K S，et al. 2026 guideline for the early management of patients with acute ischemic stroke：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2026[2026-02-02]. https://doi.org/10.1161/STR.0000000000000513.
[12] 国家卫生健康委办公厅. 国家卫生健康委办公厅关于印发2024年国家医疗质量安全改进目标的通知[EB/OL].（2024-02-01）[2025-11-11]. https://www.gov.cn/zhengce/zhengceku/202402/content_6929763.htm.
[13] 马旭东. 创新医疗质量安全管理模式，目标管理助力高质量发展[J]. 中国医刊，2021，56（5）：468-469.
MA X D. Innovative management model for healthcare quality and safety：management by objectives contributes to high-quality development[J]. Chinese Journal of Medicine，2021，56（5）：468-469.
[14] 国家神经系统疾病医疗质量控制中心. 2023年国家医疗服务与质量安全报告：神经系统疾病分册[M]. 北京：科学技术文献出版社，2024.
National Center for Healthcare Quality Management in Neurological Diseases. 2023 national report on medical service and quality safety：neurological disorders volume[M]. Beijing：Scientific and Technical Documentation Press，2024.
[15] 中国卒中学会. 缺血性卒中新再灌注治疗时代的海口宣言[J]. 中国卒中杂志，2023，18（12）：1465-1466.
Chinese Stroke Association. CSA declaration of next-generation reperfusion therapy for ischemic stroke[J]. Chin J Stroke，2023，18（12）：1465-1466.
[16] FONAROW G C，ZHAO X，SMITH E E，et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative[J]. JAMA，2014，311（16）：1632-1640.
[17] SAVER J L，FONAROW G C，SMITH E E，et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke[J]. JAMA，2013，309（23）：2480-2488.
[18] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[19] WANG Y J，JING J，MENG X，et al. The third China national stroke registry（CNSR-Ⅲ）for patients with acute ischaemic stroke or transient ischaemic attack：design，rationale and baseline patient characteristics[J]. Stroke Vasc Neurol，2019，4（3）：158-164.
[20] LIAO X L，WANG Y L，PAN Y S，et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses[J]. Stroke，2014，45（8）：2354-2358.
[21] JIA B X，REN Z G，MOKIN M，et al. Current status of endovascular treatment for acute large vessel occlusion in China：a real-world nationwide registry[J]. Stroke，2021，52（4）：1203-1212.
[22] National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med，1995，333（24）：1581-1587.
[23] DONG Q，DONG Y，LIU L P，et al. The Chinese Stroke Association scientific statement：intravenous thrombolysis in acute ischaemic stroke[J]. Stroke Vasc Neurol，2017，2（3）：147-159.
[24] WANG C J，GU H Q，ZONG L X，et al. Effectiveness of a quality improvement intervention on reperfusion treatment for patients with acute ischemic stroke：a stepped-wedge cluster randomized clinical trial[J/OL]. JAMA Netw Open，2023，6（6）：e2316465[2025-11-11]. https://doi.org/10.1001/jamanetworkopen.2023.16465.
[25] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. 2018 guidelines for the early management of patients with acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2018，49（3）：e46-e110[2025-11-11]. https://doi.org/10.1161/STR.0000000000000158.
[26] American Heart Association. Target：stroke phase Ⅲ[EB/OL]. [2025-11-11]. https://www.heart.org/en/professional/quality-improvement/target-stroke/introducing-target-stroke-phase-Ⅲ.
[27] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[28] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[29] PARSONS M W，YOGENDRAKUMAR V，CHURILOV L，et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke（TASTE）：a multicentre，randomised，controlled，phase 3 non-inferiority trial[J]. Lancet Neurol，2024，23（8）：775-786.
[30] MUIR K W，FORD G A，FORD I，et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset（ATTEST-2）：a randomised，parallel group，open-label trial[J]. Lancet Neurol，2024，23（11）：1087-1096.
[31] MENG X，LI S Y，DAI H G，et al. Tenecteplase vs. alteplase for patients with acute ischemic stroke：the ORIGINAL randomized clinical trial[J]. JAMA，2024，332（17）：1437-1445.
[32] ZHOU H Y，CHEN W Q，PAN Y S，et al. Effect of sex differences on prognosis of intravenous thrombolysis：data from the thrombolysis implementation and monitor of acute ischemic stroke in China（TIMS-China）[J]. Stroke Vasc Neurol，2021，6（1）：10-15.
[33] HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med，2008，359（13）：1317-1329.
[34] THOMALLA G，SIMONSEN C Z，BOUTITIE F，et al. MRI-guided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med，2018，379（7）：611-622.
[35] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.
[36] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（8）：701-711.
[37] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[38] ZHOU Y，HE Y D，CAMPBELL B C V，et al. Alteplase for acute ischemic stroke at 4.5 to 24 hours：the HOPE randomized clinical trial[J]. JAMA，2025，334（9）：788-797.
[39] YAN S Q，ZHOU Y，LANSBERG M G，et al. Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours[J]. N Engl J Med，2025，392（13）：1288-1296.
[40] CASAUBON L K，BOULANGER J M，BLACQUIERE D，et al. Canadian stroke best practice recommendations：hyperacute stroke care guidelines，update 2015[J]. Int J Stroke，2015，10（6）：924-940.
[41] WANG Y J，ZHAO X Q，LIU L P，et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China：the Chinese intracranial atherosclerosis（CICAS）study[J]. Stroke，2014，45（3）：663-669.
[42] CHEN H W，COLASURDO M. Endovascular thrombectomy for large ischemic strokes：meta-analysis of six multicenter randomized controlled trials[J]. J Neurointerv Surg，2025，17（6）：580-585.
[43] ADUSUMILLI G，KOBEISSI H，GHOZY S，et al. Endovascular thrombectomy after acute ischemic stroke of the basilar artery：a meta-analysis of four randomized controlled trials[J/OL]. J Neurointerv Surg，2023，15：e446-e451[2025-11-11]. https://doi.org/10.1136/jnis-2022-019776.
[44] American Association of Neurological Surgeons（AANS），American Society of Neuroradiology（ASNR），Cardiovascular and Interventional Radiology Society of Europe（CIRSE），et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke[J]. Int J Stroke，2018，13（6）：612-632.
[45] KHATRI P，ABRUZZO T，YEATTS S D，et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent[J]. Neurology，2009，73（13）：1066-1072.
[46] HACKE W，DONNAN G，FIESCHI C，et al. Association of outcome with early stroke treatment：pooled analysis of ATLANTIS，ECASS，and NINDS rt-PA stroke trials[J]. Lancet，2004，363（9411）：768-774.
[47] LANSBERG M G，SCHROOTEN M，BLUHMKI E，et al. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin scale[J]. Stroke，2009，40（6）：2079-2084.
[48] FRANSEN P S S，BERKHEMER O A，LINGSMA H F，et al. Time to reperfusion and treatment effect for acute ischemic stroke：a randomized clinical trial[J]. JAMA Neurol，2016，73（2）：190-196.
[49] MENON B K，SAJOBI T T，ZHANG Y K，et al. Analysis of workflow and time to treatment on thrombectomy outcome in the endovascular treatment for small core and proximal occlusion ischemic stroke（ESCAPE）randomized，controlled trial[J]. Circulation，2016，133（23）：2279-2286.
[50] RIBO M，MOLINA C A，COBO E，et al. Association between time to reperfusion and outcome is primarily driven by the time from imaging to reperfusion[J]. Stroke，2016，47（4）：999-1004.
[51] YI T Y，GAN S J，WU M H，et al. Comparison of endovascular therapy care and outcome in primary and comprehensive stroke centers for acute ischemic stroke in China a real-world nationwide registry[J/OL]. Front Neurol，2025，16：1655954[2025-11-13]. https://doi.org/10.3389/fneur.2025.1655954.
[52] LIEBESKIND D S，BRACARD S，GUILLEMIN F，et al. eTICI reperfusion：defining success in endovascular stroke therapy[J]. J Neurointerv Surg，2019，11（5）：433-438.
[53] CAMPBELL B C，MITCHELL P J，KLEINIG T J，et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med，2015，372（11）：1009-1018.
[54] SAVER J L，GOYAL M，BONAFE A，et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med，2015，372（24）：2285-2295.
[55] GOYAL M，DEMCHUK A M，MENON B K，et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med，2015，372（11）：1019-1030.
[56] LESLIE-MAZWI T，CHEN M，YI J，et al. Post-thrombectomy management of the ELVO patient：guidelines from the Society of NeuroInterventional Surgery[J]. J Neurointerv Surg，2017，9（12）：1258-1266.
[57] 中国卒中学会重症脑血管病分会专家撰写组. 急性缺血性脑卒中血管内治疗术后监护与管理中国专家共识[J]. 中华医学杂志，2017，97（3）：162-172.
Writing Group for the Society of Critical Care of Stroke，Chinese Stroke Association. Chinese expert consensus on postoperative monitoring and management of endovascular treatment for acute ischemic stroke[J]. Natl Med J China，2017，97（3）：162-172.
[58] BERKHEMER O A，FRANSEN P S S，BEUMER D，et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med，2015，372（1）：11-20.
[59] MOCCO J，ZAIDAT O O，VON KUMMER R，et al. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone[J]. Stroke，2016，47（9）：2331-2338.
[60] BRACARD S，DUCROCQ X，MAS J L，et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke（THRACE）：a randomised controlled trial[J]. Lancet Neurol，2016，15（11）：1138-1147.
[61] MUIR K W，FORD G A，MESSOW C M，et al. Endovascular therapy for acute ischaemic stroke：the pragmatic ischaemic stroke thrombectomy evaluation（PISTE）randomised，controlled trial[J]. J Neurol Neurosurg Psychiatry，2017，88（1）：38-44.
[62] KRUMHOLZ H M，KEENAN P S，BRUSH J E，Jr，et al. Standards for measures used for public reporting of efficiency in health care：a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research and the American College of Cardiology Foundation[J]. J Am Coll Cardiol，2008，52（18）：1518-1526.
[63] JAHAN R，SAVER J L，SCHWAMM L H，et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice[J]. JAMA，2019，322（3）：252-263.
[64] FORD A L，WILLIAMS J A，SPENCER M，et al. Reducing door-to-needle times using Toyota’s lean manufacturing principles and value stream analysis[J]. Stroke，2012，43（12）：3395-3398.
[65] WANG Y L，LI Z X，ZHAO X Q，et al. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in china：a randomized clinical trial[J]. JAMA，2018，320（3）：245-254.
[66] FONAROW G C，SMITH E E，SAVER J L，et al. Improving door-to-needle times in acute ischemic stroke：the design and rationale for the American Heart Association/American Stroke Association’s target：stroke initiative[J]. Stroke，2011，42（10）：2983-2989.
[67] ZHONG W S，LIN L T，GONG X X，et al. Evaluation of a multicomponent intervention to shorten thrombolytic door-to-needle time in stroke patients in China（MISSION）：a cluster-randomized controlled trial[J/OL]. PLoS Med，2022，19（7）：e1004034[2025-11-11]. https://doi.org/10.1371/journal.pmed.1004034.
[68] JING J，XIE X W，LENG X Y，et al. Chinese Stroke Association guidelines on emergency stroke unit[J]. Stroke Vasc Neurol，2024，9（6）：741-745.
[69] 中国卒中学会急诊卒中单元联盟. 急诊卒中单元建设指南[J]. 中国卒中杂志，2024，19（12）：1454-1459.
Emergency Stroke Unit Alliance，Chinese Stroke Association. Chinese Stroke Association guidelines on emergency stroke unit[J]. Chin J Stroke，2024，19（12）：1454-1459.
[70] PRASAD K，TIWARI S. Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease[J]. Curr Pharm Des，2017，23（6）：937-943.
[71] FONAROW G C，REEVES M J，SMITH E E，et al. Characteristics，performance measures，and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke[J]. Circ Cardiovasc Qual Outcomes，2010，3（3）：291-302.
[72] SCHWABAUER E，PICCININNI M，FREITAG E，et al. Effects of mobile stroke unit dispatch on blood pressure management and outcomes in patients with intracerebral haematoma：results from the Berlin_prehospital or usual care delivery in acute stroke（B_PROUD）controlled intervention study[J]. Eur Stroke J，2024，9（2）：366-375.
[73] BOWRY R，PARKER S，RAJAN S S，et al. Benefits of stroke treatment using a mobile stroke unit compared with standard management：the BEST-MSU study run-in phase[J]. Stroke，2015，46（12）：3370-3374.
[74] SUN C H，BHATT D L，NOGUEIRA R G，et al. Endovascular therapy for stroke：getting to the “heart” of the matter[J]. Circulation，2014，129（10）：1152-1160.
[75] MCTAGGART R A，ANSARI S A，GOYAL M，et al. Initial hospital management of patients with emergent large vessel occlusion（ELVO）：report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery[J]. J Neurointerv Surg，2017，9（3）：316-323.
[76] MCTAGGART R A，YAGHI S，BAIRD G，et al. Decreasing procedure times with a standardized approach to ELVO cases[J]. J Neurointerv Surg，2017，9（1）：2-5.
[77] SETTECASE F，MCCOY D B，DARFLINGER R，et al. Improving mechanical thrombectomy time metrics in the angiography suite：stroke cart，parallel workflows，and conscious sedation[J]. Interv Neuroradiol，2018，24（2）：168-177.
[78] FREI D，MCGRAW C，MCCARTHY K，et al. A standardized neurointerventional thrombectomy protocol leads to faster recanalization times[J]. J Neurointerv Surg，2017，9（11）：1035-1040.
[79] SCHÖNENBERGER S，UHLMANN L，HACKE W，et al. Effect of conscious sedation vs. general anesthesia on early neurological improvement among patients with ischemic stroke undergoing endovascular thrombectomy：a randomized clinical trial[J]. JAMA，2016，316（19）：1986-1996.

急性缺血性卒中再灌注治疗医疗质量评价与改进专家建议（2026）

Expert Recommendations on Evaluation and Improvement of Healthcare Quality for Reperfusion Therapy in Acute Ischemic Stroke (2026)

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	何丹丹, 李俭, 王春娟, 李姝雅. 我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破[J]. 中国卒中杂志, 2026, 21(5): 517-524.
[2]	程希玥, 赵璟妍, 王春娟. 依达拉奉右莰醇在急性缺血性卒中脑细胞保护中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 526-532.
[3]	杨千千, 张眉扬, 陆瑶, 周东杨, 王正一蕾, 单舒乙, 刘晨辉, 王伊龙, 管玲. 米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据[J]. 中国卒中杂志, 2026, 21(5): 533-542.
[4]	何丹丹, 李姝雅. 基于STAIR原则的PSD-95靶向脑细胞保护剂在急性缺血性卒中中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 543-552.
[5]	常曹文静, 许淑红, 李俭, 李姝雅. 载脂蛋白E基因与缺血性卒中后脑损伤关系的研究进展[J]. 中国卒中杂志, 2026, 21(5): 570-576.
[6]	李汶逸, 姜季委, 任琦玮, 王琳琳, 赵敏, 徐俊. 载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究[J]. 中国卒中杂志, 2026, 21(5): 577-584.
[7]	刘元昊, 吴磊, 杨欢, 朱佳颖, 李亚哲. 不同取栓装置在急性缺血性卒中治疗中的有效性与安全性：1项回顾性比较研究[J]. 中国卒中杂志, 2026, 21(4): 463-470.
[8]	欧茹, 刘益民, 徐智坚, 黄文纯. 血管源性腔隙灶对急性缺血性卒中患者生命健康状况的动态影响[J]. 中国卒中杂志, 2026, 21(3): 312-319.
[9]	李荔, 段振晖, 高爱华, 潘宋斌. 老年急性缺血性卒中患者衰弱指数、营养风险与静脉溶栓后院内感染风险的相关性分析及预测模型构建[J]. 中国卒中杂志, 2026, 21(3): 331-337.
[10]	张自立, 赵颖, 孟珩, 徐安定. 急性缺血性卒中血管内治疗后无效再通预测研究进展[J]. 中国卒中杂志, 2026, 21(3): 378-386.
[11]	杜万良. 2026美国心脏学会/美国卒中学会急性缺血性卒中患者早期管理指南静脉溶栓要点与解读[J]. 中国卒中杂志, 2026, 21(2): 226-233.
[12]	姚莉, 吴川杰. 2026美国心脏学会/美国卒中学会急性缺血性卒中患者早期管理指南血管内治疗要点与解读[J]. 中国卒中杂志, 2026, 21(2): 234-239.
[13]	熊云云, 路正钊, 马瑛, 单大卫, 吴娜, 郝曼均, 马宇洁, 武双喆, 李祉馨, 沈柯佳, 唐奕哲, 王拥军. 卒中：回眸2025[J]. 中国卒中杂志, 2026, 21(1): 1-23.
[14]	何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.
[15]	黄旭阳, 李润辉. 替奈普酶与阿替普酶治疗急性缺血性卒中短期神经功能恢复比较：线性混合效应模型分析[J]. 中国卒中杂志, 2026, 21(1): 31-37.